1. Industry Chain Analysis of Dolutegravir and Dolutegravir Generic Drugs Market
The upstream of Dolutegravir and Dolutegravir Generic Drugs are suppliers of raw materials. Midstream is the manufacturer of Dolutegravir and Dolutegravir Generic Drugs. Downstream customers are divided into children and adults.
2. Upstream Raw Material Suppliers of Dolutegravir and Dolutegravir Generic Drugs Market Analysis
The major suppliers of upstream raw materials in the Dolutegravir and Dolutegravir Generic Drugs market include Toronto Research Chemicals, Desano, Lupin, Manus Aktteva Biopharma LLP, and CLEARSYNTH.
Table Upstream Raw Material Suppliers of Dolutegravir and Dolutegravir Generic Drugs with Contact Information
Raw Material | Suppliers | Contact Information |
Dolutegravir API | Toronto Research Chemicals |
|
Desano |
| |
Lupin |
| |
Manus Aktteva Biopharma LLP |
| |
CLEARSYNTH |
|
3. Major Downstream Buyers of Dolutegravir and Dolutegravir Generic Drugs Market Analysis
Dolutegravir is used with other medicines to treat HIV infection in adults weighing at least 6.6 pounds (3 kilograms) and children 4 weeks of age and older. It is also used in combination with rilpivirine (Edurant) to treat HIV in some adults, as an alternative to their current HIV medication that they have been taking for at least 6 months. Although dolutegravir does not cure HIV, use with other medicines may reduce the chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related diseases (such as serious infections or cancer). Taking these medications and practicing safer sex and other lifestyle changes may reduce the risk of transmitting HIV to other people.
4. Dolutegravir and Dolutegravir Generic Drugs Market Drivers
‘Rising global prevalence of HIV/AIDS’
Acquired immunodeficiency syndrome (AIDS) is a potentially life-threatening chronic disease caused by the human immunodeficiency virus (HIV). HIV interferes with the body’s ability to fight infection and disease by damaging the immune system. HIV is a sexually transmitted infection (STI). The disease can also be spread through contact with infected blood and illegal injection drugs or by sharing needles, and from mother to child during pregnancy, childbirth or breastfeeding. According to the World Health Organization, HIV remains a major global public health problem, continuing to spread in all countries around the world and claiming 40.4 million [32.9 million-51.3 million] lives to date. At the end of 2022, there were an estimated 39 million [33.1 million-45.7 million] people living with HIV, two-thirds of them (25.6 million) in the WHO African Region. In 2022, 630,000 [480,000-880,000] people will die from HIV-related causes and 1.3 million [1 million-1.7 million] people will be infected with HIV. As the number of HIV-positive people rises sharply, this will drive the growth of dolutegravir and dolutegravir generic drugs industry.
‘Effectiveness in treating HIV/AIDS’
Dolutegravir and generic dolutegravir belong to a class of drugs called HIV integrase inhibitors. It works by reducing the amount of HIV in the blood and increasing the number of immune cells that help fight infections in the body. Dolutegravir is very effective at quickly suppressing someone’s viral load (the number of copies of HIV in the blood). This is important for the long-term health of the person taking it. An undetectable viral load also means a person can no longer transmit HIV to other people. In clinical trials, patients taking dolutegravir reported significantly fewer side effects than those taking efavirenz (EFV). This includes reducing central nervous system side effects such as depression and anxiety. Improved tolerability of dolutegravir should make it easier to adhere to treatment in the long term. Additionally, dolutegravir has fewer drug interactions and has a higher genetic barrier to resistance compared with EFV. Therefore, this will boost the dolutegravir and dolutegravir generics market due to its effectiveness in treating HIV/AIDS.
5. Dolutegravir and Dolutegravir Generic Drugs Market Restraints
‘Side effect’
Taking dolutegravir and dolutegravir generic drugs may affect the immune system, nervous system, and some organs. The more common side effects are mainly reflected in the nervous system and gastrointestinal tract, such as headache, dizziness, nausea, diarrhea, vomiting, flatulence, etc. In addition, the side effects of dolutegravir sodium tablets include rash, itching, fatigue, etc. The side effects caused by taking dolutegravir and dolutegravir generic drugs may have an impact on the dolutegravir and dolutegravir generic drug market. In addition, women’s concerns about whether taking dolutegravir will increase the risk of neural tube defects in their babies may have an impact on the market.
‘Some HIV patients cannot afford treatment’
Sub-Saharan Africa is home to two-thirds of the world’s people living with HIV and is the most affected region in the world, followed by Asia and the Pacific. Poor people in developing countries are thought to be at greatest risk of contracting AIDS because their immune systems have been compromised by previous infections. The poor are further at risk due to lack of access to health care services and information about HIV. People infected with HIV and AIDS may be unable to perform daily tasks, including growing food to meet nutritional needs or earning income to support their families. As a result, many people living with HIV and AIDS cannot afford dolutegravir and dolutegravir generic drugs to treat HIV.
6. Dolutegravir and Dolutegravir Generic Drugs Market Opportunities
‘Active policy’
AIDS is a progressive immune deficiency characterized by a decrease in CD4+T lymphocytes caused by human infection with human immunodeficiency virus (HIV), which can be followed by a variety of opportunistic infections, malignant tumors and central nervous system diseases in the later stages of the disease. AIDS is a serious infectious disease with great harm and high mortality. At present, there is no cure and no vaccine prevention. The United Nations has launched the Global AIDS Strategy 2021-2026, which aims to use an inequities perspective to close the gaps that are holding back progress towards ending AIDS. The Global AIDS Strategy aims to reduce the inequalities that drive the AIDS epidemic and prioritise people who do not yet have access to life-saving HIV services. In 2021, China issued the Notice on the Tax Policy for the Import of Anti-HIV Drugs from 2021 to 2030. In order to adhere to the public welfare nature of basic medical and health services and support the prevention and treatment of AIDS, from January 1, 2021 to December 31, 2030, the anti-HIV drugs entrusted by the NHC will be imported. Import duties and value-added tax on imports are exempted. Countries around the world have issued a series of policies to combat AIDS, which will help the development of anti-HIV drugs, thereby expanding the market for dolutegravir and dolutegravir generic drugs.
‘Increased awareness of early diagnosis and treatment’
A range of social, economic and demographic factors, including stigma, discrimination, income, education and geographical region, influence the diagnosis and treatment of HIV. However, early diagnosis and treatment of HIV are key to preventing HIV transmission, improving the quality of life of patients, and improving survival rates. As a result, more and more countries have stepped up efforts to disseminate knowledge about AIDS and introduced policies to prevent the spread of AIDS. Australia, for example, has developed strategies to promote early diagnosis and initiation of treatment. These include HIV testing during prenatal screenings and regular screening for sexually transmitted infections (STIs) among men who have sex with men. With the continuous improvement of people’s awareness and understanding of AIDS, people’s health awareness continues to increase, more and more AIDS patients can be found and treated earlier, which will promote the development of dolutegravir and dolutegravir generic drug industry.
7. Dolutegravir and Dolutegravir Generic Drugs Market Challenges
‘High industry barriers’
The dolutegravir and dolutegravir generic drug industry is a high-tech, high-risk, and high-investment industry. When new drugs go from research and development, clinical trials, trial production to final product market development and product promotion, a large amount of capital, technology and other resources are required to be invested in each link. The technical level, experience accumulation and other comprehensive qualities of R&D personnel are also very high. At the same time, the production of drugs also requires a lot of special equipment, which is expensive. In addition, since pharmaceutical products are closely related to people’s health, when choosing drugs, consumers tend to choose products with high reputation and good quality, and are more loyal to frequently selected drugs.
‘Labor shortage and rising labor costs’
With economic development and aging trends, labor costs in various places are gradually rising. For example, according to the latest employment data released by the U.S. Bureau of Labor Statistics, in August 2023, the average hourly wage of American workers was $33.82. In August 2022, the average hourly wage of employees was US$32.43, a year-on-year increase of 4.3%. From 2018 to 2022, hourly wages in China will grow steadily at a compound annual growth rate of 7.5%, reaching US$5.6 in 2022. It is expected that hourly wages in China will continue to grow to US$7.4 by 2027, with a compound annual growth rate of 5.8% from 2023 to 2027. Increased labor costs will affect the operations and profits of dolutegravir and dolutegravir generic drug companies. In addition, many countries around the world are currently facing labor shortages. For example, according to a report by the German Federal Labor Office, 200 of about 1,200 occupations surveyed in 2022 will experience labor shortages. About 50.5 million people quit their jobs in 2022, breaking the record set in 2021, according to the U.S. Bureau of Labor Statistics’ JOLTS report. Companies in the industry have had to raise wages to attract workers due to labor shortages and rising prices. The shortage of labor has restricted the company’s business development, and the increase in labor costs will affect the company’s operations and profits.
